Roche Holding AG Basel American Depositary Shares (RHHBY)
$41.05 0.60 (1.44%)
9:35 EDT RHHBY Stock Quote Delayed 20 Minutes
Previous Close $41.65
Market Cap 280.40B
PE Ratio -
Volume (Avg. Vol.) 759,464
Day's Range 41.04 - 41.20
52-Week Range 25.10 - 44.77
Dividend & Yield 0.92 (2.24%)
RHHBY Stock Predictions, Articles, and Roche Holding AG Basel American Depositary Shares News
- From InvestorPlace
- From the Web
Roche Holding (RHHBY) news for Friday includes an update on testing for the coronavirus from China with approval from the FDA.
One of the best mutual funds last year was the T. Rowe Price Health Sciences Fund. Here are 7 healthcare stocks to buy from its holdings.
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by....
Why NewLink Genetics Corp (NLNK), Urban Outfitters, Inc. (URBN) and Dell Technologies Inc (DVMT) Are 3 of Today’s Worst Stocks
Dell Technologies (DVMT), NewLink Genetics (NLNK) and Urban Outfitters (URBN) shareholders couldn't wait for Thursday's action to come to a close.
Biotechnology is among the most exciting and lucrative sectors for investors, and these 3 biotech stocks stand out...
The iShares MSCI EAFE ETF (EFA) holds nearly 940 stocks based outside the U.S. Is the EFA the right way to get international exposure?
I've uncovered a data set that show Switzerland as the most innovative country in the world. Here's how to take advantage...
By Richard Band
Roche has plenty of great drugs under its umbrella and RHHBY stock should do well no matter what the government decides to do.
Analysts are divided on if they think this bull market can last, but agree its a bumpy ride. Smooth it over with these ETF plays
By Richard Band
The Big Pharma is set to have a very good 2017 and put 2016 behind it.
Medical is one of the sectors that is witnessing earnings and revenue growth this quarter, and these 5 healthcare stocks are set to beat
Eleven Biotherapeutics stock soared on Monday following news of its deal with Roche concerning its Interleukin-6 technology.
Johnson & Johnson is one of the strongest dividend payers the market's have to offer. Here's why I'm willing to pay a premium to own JNJ stock
Big data can be used by big pharma companies like Roche to drastically cut costs, increase drug production and drive long-term stock gains.
The introduction of biosimilar drugs will change the biotech landscape ... especially for these three names.
With Q4 earnings season upon us, better-than-expected gains from companies based partly or mostly on lower oil prices may be just the salve the market needs to regain some traction.
Gilead's breakthrough Hepatitis C drug, Sovaldi®, will drive revenue and profits for the rest of 2014 and into 2015.
From Talk Markets
From The Motley Fool